All In Biotech

Drug Trial Radar · NCT04417530

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Aug 5, 2020

Primary completion

Apr 22, 2024

Study completion Apr 22, 2024

Sponsor

Lead sponsor
Aura BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

Conditions

  • Uveal Melanoma
  • Ocular Melanoma
  • Choroidal Melanoma

Interventions

  • AU-011Drug

    AU-011 Via Suprachoroidal Administration

  • Suprachoroidal MicroinjectorDevice

    Suprachoroidal Injection Device

  • PDT LaserDevice

    Laser Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment related AEs and treatment related serious adverse events (SAEs).Time frame: 52 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Associates SW, P.C.

    Tucson, Arizona

  • UCLA Jules Stein Eye Institute

    Los Angeles, California

  • Byers Eye Institute at Stanford University

    Palo Alto, California

  • UCHealth Eye Center

    Aurora, Colorado

  • Retina Associates of Florida

    Tampa, Florida

  • Emory Eye Center

    Atlanta, Georgia

  • University of Illinois At Chicago Illinois Eye and Ear Infirmary

    Chicago, Illinois

  • Midwest Eye Institute

    Carmel, Indiana

  • University of Iowa Department of Ophthalmology and Visual Sciences

    Iowa City, Iowa

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts

  • W. K. Kellogg Eye Center, University of Michigan

    Ann Arbor, Michigan

  • Associated Retinal Consultants, PC

    Royal Oak, Michigan

  • Retina Center

    Minneapolis, Minnesota

  • Columbia University Medical Center

    New York, New York

  • Dean McGee Eye Institute

    Oklahoma City, Oklahoma

  • Oregon Health & Science University Casey Eye Institute

    Portland, Oregon

  • Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Retina Consultants of Carolina, PA

    Greenville, South Carolina

  • St. Thomas Health / Tennessee Retina, PC

    Nashville, Tennessee

  • Texas Retina Associates

    Dallas, Texas

  • Retina Consultants of Houston

    Houston, Texas

  • University of Wisconsin Dept of Ophthalmology & Visual Sciences

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.